The Motley Fool··Jonathan PoncianoBVF's $52M Stake in Disc Medicine Signals Confidence Despite Regulatory Hurdles
BVF Partners invests $52M in Disc Medicine despite FDA setbacks, betting on Phase 3 trial data and strong cash reserves through 2029.
KYMRRVMDRVMDWIRONFDA approvalclinical trial